News | August 26, 2025
Merck presents new data on cardiovascular disease at ESC Congress 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The initiative was announced at World Hypertension Congress, Chennai
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Subscribe To Our Newsletter & Stay Updated
